Composition for preventing, alleviating, or improving heat stroke or dehydration containing ergothioneine or salt thereof, and composition for regulating intracellular and extracellular water content

MYPI2025005835A0Undetermined Publication Date: 2024-09-28SUNTORY HLDG LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025005835
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-28
Filing Date
2024-03-21
Publication Date
2024-09-28

AI Technical Summary

Technical Problem

Aging leads to a disruption in the balance of intracellular and extracellular water in the body, increasing the proportion of extracellular fluid and impairing thermoregulation, resulting in conditions like heat stroke and dehydration, for which existing solutions are inadequate.

Method used

Compositions containing L-ergothioneine or its salts, which regulate intracellular and extracellular water by lowering the extracellular water ratio, effectively preventing, alleviating, or improving heat stroke and dehydration.

Benefits of technology

The use of L-ergothioneine or its salts in compositions reduces the extracellular water ratio, enhancing body fluid balance and improving heat stroke and dehydration symptoms by promoting moisture retention and reducing dryness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025005835_DRAWING_001
    Figure PI2025005835_DRAWING_001
Patent Text Reader

Abstract

The present invention aims to provide a composition that regulates intracellular and extracellular water and that is useful for preventing, alleviating, or ameliorating heat-related illness or dehydration. The present invention relates to, for example, a composition for preventing, alleviating, or ameliorating heat-related illness, containing L-ergothioneine or a salt thereof. Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

Composition for preventing, alleviating or ameliorating heatstroke or dehydration, and composition for regulating intracellular and extracellular water, containing ergothioneine or its salt

[0001] The present invention relates to a composition for preventing, alleviating, or ameliorating heatstroke. The present invention also relates to a composition for preventing, alleviating, or ameliorating dehydration. The present invention further relates to a composition for regulating intracellular and extracellular water. The present invention further relates to a method for preventing, alleviating, or ameliorating heatstroke, a method for preventing, alleviating, or ameliorating dehydration, a method for regulating intracellular and extracellular water, etc.

[0002] Water is the most abundant compound in the human body. Water in the body plays an important role in maintaining life, such as regulating body temperature and transporting oxygen, nutrients, and waste products. Approximately two-thirds of the body's water exists as intracellular fluid within various cells, and the remaining approximately one-third exists as extracellular fluid. Extracellular fluid is divided into plasma, interstitial fluid, and lymph.

[0003] Body water tends to decrease with age. Both intracellular and extracellular fluids decrease, but the rate of decrease in intracellular fluid is greater than that of extracellular fluid, resulting in an increase in the proportion of extracellular fluid. When the proportion of extracellular fluid in body water increases due to factors such as aging, disrupting the balance between intracellular and extracellular water, it can cause various problems, such as a decline in thermoregulatory function. For example, a decline in thermoregulatory function can lead to heatstroke and dehydration. Therefore, regulating intracellular and extracellular water is expected to prevent, reduce, or improve heatstroke and dehydration.

[0004] Ergothioneine is an amino acid found in mushrooms and the like, and exists naturally in the L-form. L-ergothioneine is known to have physiological effects such as antioxidant activity. Regarding the physiological effects of ergothioneine, for example, Patent Document 1 reports that it has the effect of activating immune responses and promoting cytokine production.

[0005] JP 2017-218431 A

[0006] An object of the present invention is to provide a composition that regulates intracellular and extracellular water content and is useful for preventing, alleviating, or ameliorating heatstroke or dehydration.

[0007] As a result of intensive research aimed at solving the above-mentioned problems, the present inventors have found that L-ergothioneine or a salt thereof has the effect of decreasing the ratio of extracellular water volume to the total amount of intracellular water and extracellular water volume (extracellular water volume / (total amount of intracellular water and extracellular water volume)). L-ergothioneine or a salt thereof has the effect of regulating intracellular and extracellular water volume and is useful for preventing, alleviating, or ameliorating heatstroke and dehydration.

[0008] That is, the present invention relates to the following compositions, including, but not limited to, a composition for preventing, alleviating, or ameliorating heatstroke, a composition for preventing, alleviating, or ameliorating dehydration, and a composition for regulating intracellular and extracellular water: [1] A composition for preventing, alleviating, or ameliorating heatstroke, comprising L-ergothioneine or a salt thereof. [2] The composition according to [1] above, which prevents, alleviates, or ameliorate heatstroke by regulating intracellular and extracellular water. [3] The composition according to [1] or [2] above, which is labeled with at least one function selected from the group consisting of "prevention, alleviation, or amelioration of heatstroke," "prevention of heatstroke from worsening," "regulation of intracellular and extracellular water," "moisture retention," and "prevention, alleviation, or amelioration of dryness." [4] A composition for preventing, alleviating, or ameliorating dehydration, comprising L-ergothioneine or a salt thereof. [5] The composition according to [4] above, which prevents, alleviates, or ameliorate dehydration by regulating intracellular and extracellular water. [6] The composition according to [4] or [5] above, which is labeled with at least one function selected from the group consisting of "prevention, alleviation, or amelioration of dehydration," "prevention of worsening dehydration," "regulation of intracellular and extracellular water," "water retention," and "prevention, alleviation, or amelioration of dryness." [7] A composition for regulating intracellular and extracellular water, comprising L-ergothioneine or a salt thereof. [8] The composition according to [7] above, which is used to reduce the ratio of extracellular water to the total amount of intracellular and extracellular water in humans. [9] The composition according to [7] or [8] above, which is labeled with at least one function selected from the group consisting of "prevention, alleviation, or amelioration of heatstroke," "prevention of worsening heatstroke," "prevention, alleviation, or amelioration of dehydration," "prevention of worsening dehydration," "regulation of intracellular and extracellular water," "water retention," and "prevention, alleviation, or amelioration of dryness."

[10] The composition according to any of [1] to [9] above, which is an oral composition.

[11] The composition according to any of [1] to

[10] above, which is a food or drink.

[12] A method for preventing, alleviating, or ameliorating heatstroke, which comprises administering L-ergothioneine or a salt thereof.

[13] A method for preventing, alleviating, or ameliorating dehydration, which comprises administering L-ergothioneine or a salt thereof.

[14] A method for regulating intracellular and extracellular water content, which comprises administering L-ergothioneine or a salt thereof.

[15] Use of L-ergothioneine or a salt thereof for preventing, alleviating, or ameliorating heatstroke.

[16] Use of L-ergothioneine or a salt thereof for preventing, alleviating, or ameliorating dehydration.

[17] Use of L-ergothioneine or a salt thereof for regulating intracellular and extracellular water.

[0009] According to the present invention, a composition can be provided that regulates intracellular and extracellular water content and is useful for preventing, alleviating, or ameliorating heatstroke or dehydration.

[0010] Figure 1 is a graph showing the measured uric acid / urea values ​​for the test food group and the control food group. Figure 2 is a graph showing the change in uric acid / urea values ​​(Δuric acid / urea) for the test food group and the control food group.

[0011] The composition of the present invention for preventing, alleviating, or ameliorating heatstroke contains L-ergothioneine or a salt thereof. The composition of the present invention for preventing, alleviating, or ameliorating heatstroke may also be referred to as the composition of the first aspect of the present invention. Heatstroke refers to a state in which the thermoregulatory function is impaired due to a hot and humid environment, causing heat to build up in the body.

[0012] The composition of the present invention for preventing, alleviating, or ameliorating dehydration contains L-ergothioneine or a salt thereof. The composition of the present invention for preventing, alleviating, or ameliorating dehydration may also be referred to as the composition of the second aspect of the present invention. Dehydration refers to a state in which the body is deficient in water.

[0013] The composition of the present invention for regulating intracellular and extracellular water contains L-ergothioneine or a salt thereof. The composition of the present invention for regulating intracellular and extracellular water may also be referred to as the composition of the third aspect of the present invention. In this specification, the composition of the first aspect, the composition of the second aspect, and the composition of the third aspect of the present invention may also be collectively referred to as the composition of the present invention. The composition of the present invention contains L-ergothioneine or a salt thereof as an active ingredient.

[0014] L-ergothioneine is a type of sulfur-containing amino acid. The salt of L-ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for use in foods and beverages, and may be either an acidic salt or a basic salt. Examples of acidic salts include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; and organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate. Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; and alkaline earth metal salts such as calcium salt and magnesium salt.

[0015] L-ergothioneine or a salt thereof is not limited in any way by its form, production method, etc. Ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from a natural product. L-ergothioneine is contained in large amounts in the Golden / Yellow Oyster Mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), a mushroom of the Pleurotus genus in the family Pleurotus. L-ergothioneine is found in mushrooms such as white button mushrooms, crimini mushrooms, and portabella mushrooms (Agaricus bisporus), Grey Oyster Mushrooms (Pleurotus ostreatus), shiitake mushrooms (Lentinula edodes), Maitake mushrooms (Grifola frondosa), reishi mushrooms (Ganoderma lucidum), Yamabushitake mushrooms (Hericium erinaceus), Yanagimatsutake mushrooms (Agrocybe aegerita), and chanterelle mushrooms (Cantharella verruca). It is also contained in mushrooms such as Pleurotus cibarius, porcini mushroom (scientific name: Boletus edulis), and morel mushroom (scientific name: Morchella esculenta). When obtaining L-ergothioneine from a natural product, it is preferably extracted from Pleurotus cornucopiae. L-ergothioneine or a salt thereof can also be produced by microbial fermentation. L-ergothioneine or a salt thereof may be isolated.

[0016] L-ergothioneine or a salt thereof is a compound that is contained in natural products and foods and beverages and has been consumed as a dietary source. Therefore, from the viewpoint of safety, L-ergothioneine or a salt thereof is considered to pose few problems, even when taken over a long period of time. The present invention can provide a highly safe composition for preventing, reducing, or ameliorating heatstroke, a composition for preventing, reducing, or ameliorating dehydration, and a composition for regulating intracellular and extracellular water content.

[0017] In one embodiment, the composition of the first aspect of the present invention can be used to prevent, reduce or improve heat stroke by regulating intracellular and extracellular water content, while the composition of the second aspect of the present invention can be used to prevent, reduce or improve dehydration by regulating intracellular and extracellular water content.

[0018] In the present invention, regulation of intracellular and extracellular water refers to regulation of intracellular water volume and extracellular water volume. Intracellular water volume refers to the amount of water present within cells (intracellular fluid) among the water in the body, and extracellular water volume refers to the amount of water present outside cells (extracellular fluid). An index showing water localization in the body is the ratio of extracellular water volume to the total amount of intracellular water and extracellular water (extracellular water volume / (total amount of intracellular water and extracellular water)). The total amount of intracellular water and extracellular water is total body water (total body water). The ratio of extracellular water volume to the total amount of intracellular water and extracellular water is sometimes referred to as the extracellular water ratio. In the present invention, regulation of intracellular and extracellular water includes regulation of the ratio of extracellular water volume to the total amount of intracellular water and extracellular water (extracellular water ratio).

[0019] In the present invention, regulating intracellular and extracellular water preferably means reducing the ratio of extracellular water to the total amount of intracellular and extracellular water (extracellular water ratio). Intracellular water acts as a water reservoir, migrating outside the cells to replenish extracellular water when the extracellular water is reduced. By reducing the extracellular water ratio, the intracellular water ratio is increased, and when extracellular water is lost, body fluids can quickly move from the intracellular water to compensate for the extracellular water loss. Therefore, reducing the extracellular water ratio is effective in preventing, alleviating, or ameliorating heatstroke and dehydration. Substances that regulate the extracellular water ratio, particularly those that reduce the extracellular water ratio, are useful for preventing, alleviating, or ameliorating heatstroke and dehydration.

[0020] In the present invention, the ratio of the extracellular water volume to the total amount of intracellular water and extracellular water (extracellular water ratio) can be evaluated by the ratio of uric acid (mg / dL) to urea (mg / dL) in blood (uric acid / urea). It is known that blood uric acid levels reflect the amount of extracellular water, and blood urea levels reflect the amount of total body water (the total amount of intracellular and extracellular water) (e.g., J Artif Organs. 2022 Dec 24 (doi: 10.1007 / s10047-022-01377-6), Kawaguchi Y., "The uric acid-urea distribution volume ratio is a potential marker of hydration status in patients on hemodialysis."). A decrease in the above uric acid / urea levels indicates a decrease in the extracellular water ratio.

[0021] As shown in the Examples below, L-ergothioneine has the effect of lowering the ratio of uric acid concentration to urea concentration in blood (uric acid / urea). Thus, L-ergothioneine or a salt thereof has the effect of regulating intracellular and extracellular water. L-ergothioneine or a salt thereof can be used to lower the ratio of extracellular water to the total amount of intracellular and extracellular water. The composition of the present invention containing L-ergothioneine or a salt thereof is useful as a new means for preventing, alleviating, or ameliorating heatstroke and dehydration, in addition to the conventional method of replenishing water and salt, which is to prevent, alleviate, or ameliorate heatstroke and dehydration.

[0022] L-ergothioneine or a salt thereof can be used to lower the ratio of uric acid concentration to urea concentration in blood (uric acid / urea). L-ergothioneine or a salt thereof can be used as an active ingredient for lowering the ratio of uric acid concentration to urea concentration in blood (uric acid / urea). The present invention also encompasses a composition for lowering the ratio of uric acid concentration to urea concentration in blood (uric acid / urea), which comprises L-ergothioneine or a salt thereof.

[0023] The compositions of the present invention can be used to prevent, alleviate, or ameliorate conditions or diseases for which regulation of extracellular water is effective in preventing, alleviating, or ameliorating them. The compositions of the present invention can be preferably used to prevent, alleviate, or ameliorate conditions or diseases for which a decrease in the extracellular water ratio is effective in preventing, alleviating, or ameliorating them. Preventing a condition or disease includes preventing onset, delaying onset, reducing the incidence, reducing the risk of onset, etc. Alleviating a condition or disease includes alleviating the symptoms of the condition or disease. Ameliorating a condition or disease includes recovering a subject from the condition or disease, ameliorating the symptoms of the condition or disease, delaying or preventing the progression of the condition or disease, etc. Recovery includes partial recovery.

[0024] The composition of the present invention can be applied to either therapeutic (medical) or non-therapeutic (non-medical) uses. Non-therapeutic is a concept that does not include medical procedures, i.e., human surgery, treatment, or diagnosis. The composition of the present invention can be provided in the form of an agent, for example, but is not limited to this form. The agent can also be provided as a composition itself, or as a composition containing the agent. In one aspect, the composition of the first aspect of the present invention can also be referred to as an agent for preventing, alleviating, or ameliorating heatstroke. The composition of the second aspect of the present invention can also be referred to as an agent for preventing, alleviating, or ameliorating dehydration. The composition of the third aspect of the present invention can also be referred to as an intracellular and extracellular water regulating agent.

[0025] The composition of the present invention may be either an oral composition or a parenteral composition, but is preferably an oral composition. Specific examples of oral compositions include foods and beverages, oral pharmaceuticals, quasi-drugs, feed, etc., and are preferably foods and beverages or oral pharmaceuticals, more preferably foods and beverages. The composition of the present invention may be a material or preparation to be incorporated into foods and beverages, pharmaceuticals, quasi-drugs, feed, etc.

[0026] The composition of the present invention may contain any additives and any components in addition to L-ergothioneine or a salt thereof, as long as the effects of the present invention are not impaired. These additives and components can be selected depending on the form of the composition, etc. When the composition of the present invention is an oral composition, additives and the like that can generally be used in oral compositions such as foods and beverages, pharmaceuticals, quasi-drugs, and feeds can be used.

[0027] When the composition of the present invention is used in the form of a food or drink, a pharmaceutical product, a quasi-drug, a feed, etc., the method for producing the composition is not particularly limited, and the composition can be produced by a general method. The form of the oral composition of the present invention is not particularly limited, and the composition may be in the form of a solid (powder, granules, tablet, etc.), a liquid, a paste, etc.

[0028] For example, when the composition of the present invention is made into a food or beverage, various foods and beverages can be prepared by blending L-ergothioneine or a salt thereof with ingredients that can be used in foods and beverages (e.g., food ingredients, food additives used as needed, etc.). The foods and beverages are not particularly limited, and examples include general foods and beverages, health foods, health supplements, health drinks, foods with functional claims, foods for specified health uses, and foods and beverages for patients. The health foods, health supplements, foods with functional claims, foods for specified health uses, etc. can be used in various dosage forms, such as fine granules, tablets, granules, powders, capsules, chewable tablets, dry syrups, syrups, liquids, beverages, drinks, and liquid diets.

[0029] When the composition of the present invention is used as a pharmaceutical or quasi-drug, for example, L-ergothioneine or a salt thereof can be blended with a pharmacologically acceptable carrier and, if necessary, additives to produce a pharmaceutical or quasi-drug in various dosage forms. Such carriers, additives, etc. may be any pharmacologically acceptable carriers that can be used in pharmaceuticals or quasi-drugs, and examples thereof include one or more of excipients, binders, disintegrants, lubricants, antioxidants, colorants, etc. The pharmaceutical or quasi-drug may be administered (ingested) orally or parenterally (transdermally, transmucosally, enterally, by injection, etc.). When the composition of the present invention is used as a pharmaceutical or quasi-drug, it is preferably an oral pharmaceutical or oral quasi-drug. Dosage forms for oral administration of pharmaceuticals or quasi-drugs include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, chewable tablets, etc. Dosage forms for parenteral administration include, for example, injections, drip infusions, ointments, lotions, patches, suppositories, nasal preparations, pulmonary preparations (inhalants), etc. The pharmaceutical product may be a pharmaceutical product for non-human animals.

[0030] When the composition of the present invention is used as feed, L-ergothioneine or a salt thereof may be blended into the feed. Feed also includes feed additives. Examples of feed include livestock feed for cows, pigs, chickens, sheep, horses, etc.; small animal feed for rabbits, rats, mice, etc.; and pet food for dogs, cats, small birds, etc.

[0031] The subject (which can also be referred to as the administration subject) to which the composition of the present invention is ingested or administered is not particularly limited. Preferably, the subject is a human or a non-human mammal, more preferably a human. In one embodiment, the administration subject includes a subject who needs or desires the prevention, alleviation, or amelioration of heatstroke; a subject who needs or desires the prevention, alleviation, or amelioration of dehydration; a subject who needs or desires the regulation of intracellular and extracellular water; and a subject who needs or desires the prevention, alleviation, or amelioration of a condition or disease for which regulation of intracellular and extracellular water is effective in preventing, alleviating, or ameliorating the condition or disease. Examples of such subjects include middle-aged and elderly people. Middle-aged and elderly people include elderly people. Middle-aged and elderly people may be, for example, people aged 40 or older. In one embodiment, among middle-aged and elderly people, elderly people are preferred as the subject. This is because heatstroke and dehydration tend to occur particularly easily in elderly people. Elderly people may be, for example, people aged 60 or older or 65 or older. The administration subject may be a healthy individual. The composition of the present invention can also be used in healthy individuals, for example, for the purpose of preventing heatstroke, dehydration, etc.

[0032] In one embodiment, the composition of the present invention can be preferably used to reduce the ratio of extracellular water to the total amount of intracellular and extracellular water in humans.

[0033] The content of L-ergothioneine or a salt thereof in the composition of the present invention is not particularly limited and can be set depending on the form, etc. The content of L-ergothioneine or a salt thereof in the composition of the present invention is, for example, preferably 0.0001% by weight or more, more preferably 0.001% by weight or more, and preferably 90% by weight or less, more preferably 50% by weight or less, calculated as L-ergothioneine. In one aspect, the content of L-ergothioneine or a salt thereof in the composition of the present invention is preferably 0.0001 to 90% by weight, more preferably 0.001 to 50% by weight, calculated as L-ergothioneine. The content of L-ergothioneine or a salt thereof can be measured by high-performance liquid chromatography (HPLC).

[0034] In this specification, the term "quantity in terms of L-ergothioneine" or similar expressions means the amount as L-ergothioneine. More specifically, the term "quantity in terms of L-ergothioneine" or similar expressions means the amount of L-ergothioneine in the case of L-ergothioneine, and in the case of a salt of L-ergothioneine, means the value obtained by multiplying the number of moles of the salt by the molecular weight of L-ergothioneine.

[0035] The composition of the present invention can be ingested or administered by an appropriate method depending on its form. In one embodiment, the composition of the present invention is preferably ingested orally (orally administered). The dosage (which can also be referred to as intake amount) of the composition of the present invention is not particularly limited, and may be an amount that can prevent, reduce, or improve heatstroke, prevent, reduce, or improve dehydration, or regulate intracellular and extracellular water, and may be appropriately determined depending on the dosage form, administration method, subject weight, etc.

[0036] In one embodiment, when the composition of the present invention is orally ingested or administered to a human (adult), the dosage of L-ergothioneine or a salt thereof is preferably 2 mg or more, more preferably 5 mg or more, even more preferably 7 mg or more, and preferably 50 mg or less, more preferably 25 mg or less, and even more preferably 20 mg or less per day, in terms of L-ergothioneine. In one embodiment, the dosage of the composition of the present invention, as the L-ergothioneine-equivalent dosage of L-ergothioneine or a salt thereof, is preferably 2 to 50 mg, more preferably 5 to 25 mg, even more preferably 5 to 20 mg, and even more preferably 7 to 20 mg per day for a human (adult). It is preferable to ingest or administer the above amount once or more times a day, for example, once a day or in divided doses (e.g., 2 to 3 times a day). In one embodiment, it is preferable to orally ingest or administer the above amount of L-ergothioneine or a salt thereof to a human. The above dosage may be per 60 kg of body weight. In one embodiment, the composition of the present invention can be used to make a human ingest or administer the above-mentioned amount of L-ergothioneine or a salt thereof per day, for example, per 60 kg body weight.

[0037] The content of L-ergothioneine or a salt thereof in the composition of the present invention is preferably 2 to 50 mg, more preferably 5 to 25 mg, even more preferably 5 to 20 mg, and particularly preferably 7 to 20 mg, of L-ergothioneine per daily intake for an adult.

[0038] The composition of the present invention may be labeled, for example, with an indication that it regulates intracellular and extracellular water content, or with an indication of a function exhibited by regulating intracellular and extracellular water content. The composition of the first aspect of the present invention may be labeled, for example, with an indication of a function that it prevents, alleviates, or improves heatstroke. The composition of the first aspect of the present invention may be labeled, for example, with an indication of at least one function selected from the group consisting of "prevention, alleviation, or improvement of heatstroke," "prevention of heatstroke from worsening," "regulation of intracellular and extracellular water content," "moisture retention," and "prevention, alleviation, or improvement of dryness."

[0039] The composition of the second aspect of the present invention may be labeled with, for example, an indication of a function to prevent, reduce, or improve dehydration. The composition of the second aspect of the present invention may be labeled with, for example, an indication of at least one function selected from the group consisting of "prevention, reduction, or improvement of dehydration," "prevention of worsening dehydration," "regulation of intracellular and extracellular water," "moisture retention," and "prevention, reduction, or improvement of dryness."

[0040] The composition of the third aspect of the present invention may be labeled with at least one function selected from the group consisting of, for example, "prevention, alleviation, or amelioration of heat stroke," "prevention of worsening of heat stroke," "prevention, alleviation, or amelioration of dehydration," "prevention of worsening of dehydration," "regulation of intracellular and extracellular water," "moisture retention," and "prevention, alleviation, or amelioration of dryness."

[0041] In one embodiment, the composition of the present invention is preferably a food or drink labeled with the above-mentioned label. The above-mentioned label may also be a label indicating that the composition is used to obtain the above-mentioned function. The above-mentioned label may be attached to the composition itself, or to a container or packaging of the composition.

[0042] The present invention also encompasses the following methods. A method for preventing, alleviating, or ameliorating heatstroke by administering L-ergothioneine or a salt thereof. A method for preventing, alleviating, or ameliorating dehydration by administering L-ergothioneine or a salt thereof. A method for regulating intracellular and extracellular water by administering L-ergothioneine or a salt thereof. A method for lowering the ratio of uric acid concentration to urea concentration in blood (uric acid / urea) by administering L-ergothioneine or a salt thereof. The above methods may be therapeutic or non-therapeutic.

[0043] The present invention also encompasses the following uses. Use of L-ergothioneine or a salt thereof for preventing, alleviating, or ameliorating heatstroke. Use of L-ergothioneine or a salt thereof for preventing, alleviating, or ameliorating dehydration. Use of L-ergothioneine or a salt thereof for regulating intracellular and extracellular water. Use of L-ergothioneine or a salt thereof for lowering the ratio of uric acid concentration to urea concentration (uric acid / urea) in blood. The above uses may be therapeutic or non-therapeutic. By administering L-ergothioneine or a salt thereof to a subject, intracellular and extracellular water can be regulated in the subject.

[0044] In the above-mentioned methods and uses, the preferred embodiment of L-ergothioneine or a salt thereof is the same as that of the composition of the present invention described above. In the above-mentioned methods and uses, it is preferable to administer (ingest) L-ergothioneine or a salt thereof to a subject at least once a day, for example, once to several times (e.g., 2 to 3 times) a day. In the above-mentioned methods and uses, it is preferable to orally administer (ingest) L-ergothioneine or a salt thereof. The above-mentioned uses are preferably used in humans or non-human mammals, more preferably in humans.

[0045] In the above-mentioned methods and uses, L-ergothioneine or a salt thereof may be used in an amount sufficient to achieve the desired effect (which may also be referred to as an effective amount). The preferred dosage and administration targets of L-ergothioneine or a salt thereof are the same as those for the composition of the present invention described above. L-ergothioneine or a salt thereof may be administered directly or as a composition containing it. For example, the composition of the present invention described above may be used.

[0046] The present invention also encompasses the use of L-ergothioneine or a salt thereof for producing a composition for preventing, alleviating, or ameliorating heatstroke (which may also be referred to as a composition for preventing, alleviating, or ameliorating heatstroke). The present invention also encompasses the use of L-ergothioneine or a salt thereof for producing a composition for preventing, alleviating, or ameliorating dehydration (which may also be referred to as a composition for preventing, alleviating, or ameliorating dehydration). The present invention also encompasses the use of L-ergothioneine or a salt thereof for producing a composition for regulating intracellular and extracellular water (which may also be referred to as a composition for regulating intracellular and extracellular water). The present invention also encompasses the use of L-ergothioneine or a salt thereof for producing a composition for lowering the ratio of uric acid concentration to urea concentration in blood (uric acid / urea).

[0047] In this specification, a numerical range expressed by a lower limit and an upper limit, i.e., "lower limit to upper limit," includes both the lower limit and the upper limit. For example, a range expressed by "1 to 2" means 1 or more and 2 or less, including 1 and 2. In this specification, the upper and lower limits may be combined to form a range. All academic and patent literature mentioned in this specification is incorporated herein by reference.

[0048] The present invention will be described in more detail below with reference to examples, but the scope of the present invention is not limited to these examples.

[0049] Example 1: (Evaluation test of blood intracellular / extracellular water ratio markers in humans) To evaluate the effect of an ergothioneine-containing supplement on blood intracellular / extracellular water ratio marker values ​​in humans, a placebo-controlled, randomized, double-blind, parallel-group comparative study was conducted in adult men and women (46 in the test food group, 46 in the control food group, a total of 92 subjects) who ingested one capsule containing 20 mg of ergothioneine (test food) or one capsule without ergothioneine (control food) per day for four weeks. Prior to the start of the study (before initiating ingestion of the test food or control food), the subjects' blood intracellular / extracellular water ratio marker values ​​were measured as a pre-test. After four weeks of ingestion of the test food or control food, the subjects' blood intracellular / extracellular water ratio marker values ​​were measured again (week 4 test). The intracellular / extracellular water ratio marker measured was the ratio of uric acid to urea in the blood (uric acid / urea). The measurement values ​​of the intracellular / extracellular water ratio markers were calculated from the measurement values ​​of blood uric acid concentration (mg / dL) and urea concentration (mg / dL). Significant differences between groups were tested using a two-sample t-test (vs. the control food group).

[0050] (Evaluation foods) Two types of evaluation foods were used, which were indistinguishable in appearance, flavor, etc. Subjects in the test food group ingested the test food, and subjects in the control food group ingested the control food. - Test food: Capsules containing the test substance (20 mg of L-ergothioneine) - Control food: Capsules not containing the test substance In addition to the test substance, the ingredients of each evaluation food include dextrin, hydroxypropyl cellulose, carrageenan, potassium chloride, and titanium oxide. The control food was manufactured using the same ingredients as the test foods, except that it did not contain the test substance (L-ergothioneine).

[0051] Figures 1 and 2 show the measured values ​​and changes in uric acid / urea at the pre-test and the 4-week test. The change was calculated for each subject by subtracting the uric acid / urea measured value at the pre-test from the uric acid / urea measured value at the 4-week test (measurement value at the 4-week test - measurement value at the pre-test). The change in uric acid / urea value at the pre-test was set to 0. The results shown in Figures 1 and 2 are the mean value ± standard error for each group. A two-sample t-test (vs. the control food group) was used to test for significance between groups.

[0052] Figure 1 is a graph showing the measured uric acid / urea values ​​for the test food group and the control food group. In Figures 1 and 2, the black squares and solid lines represent the test food group, and the white squares (□) and dashed lines represent the control food group.

[0053] 2 is a graph showing the change in uric acid / urea levels (Δuric acid / urea) in the test food group and the control food group. As a result, uric acid / urea levels were lower in the test food group than in the control food group.

[0054] The above results demonstrate that L-ergothioneine or a salt thereof has the effect of lowering uric acid / urea levels. It is known that uric acid levels in blood reflect extracellular water volume, and urea levels in blood reflect total body water volume (the total amount of intracellular and extracellular water), and uric acid / urea levels serve as an index of the balance of intracellular and extracellular water. A decrease in uric acid / urea levels indicates a decrease in the ratio of extracellular water volume to the total amount of intracellular and extracellular water. Thus, L-ergothioneine demonstrated the effect of regulating the balance of intracellular and extracellular water.

Claims

1. A composition for preventing, alleviating or ameliorating heatstroke, comprising L-ergothioneine or a salt thereof.

2. The composition according to claim 1, which prevents, reduces or ameliorates heatstroke by regulating intracellular and extracellular water.

3. The composition according to claim 1 or 2, which is labeled with at least one function selected from the group consisting of "prevention, alleviation or amelioration of heat stroke," "prevention of aggravation of heat stroke," "regulation of intracellular and extracellular water," "moisture retention," and "prevention, alleviation or amelioration of dryness." 4. A composition for preventing, alleviating or ameliorating dehydration, comprising L-ergothioneine or a salt thereof.

5. The composition according to claim 4, which prevents, reduces or improves dehydration by regulating intracellular and extracellular water.

6. The composition according to claim 4 or 5, which is labeled with at least one function selected from the group consisting of "prevention, alleviation or amelioration of dehydration," "prevention of worsening dehydration," "regulation of intracellular and extracellular water," "moisture retention," and "prevention, alleviation or amelioration of dryness." 7. A composition for regulating intracellular and extracellular water, comprising L-ergothioneine or a salt thereof.

8. The composition according to claim 7, which is used to reduce the ratio of extracellular water to the total amount of intracellular water and extracellular water in a human.

9. The composition according to claim 7 or 8, which is labeled with at least one function selected from the group consisting of "prevention, alleviation or amelioration of heat stroke," "prevention of worsening of heat stroke," "prevention, alleviation or amelioration of dehydration," "prevention of worsening of dehydration," "regulation of intracellular and extracellular water," "moisture retention," and "prevention, alleviation or amelioration of dryness." 10. The composition according to any one of claims 1, 4 and 7, which is an oral composition.

11. The composition according to claim 10, which is a food or drink.

12. A method for preventing, alleviating, or ameliorating heatstroke by administering L-ergothioneine or a salt thereof.

13. A method for preventing, alleviating, or ameliorating dehydration by administering L-ergothioneine or a salt thereof.

14. A method for regulating intracellular and extracellular water by administering L-ergothioneine or a salt thereof.

15. Use of L-ergothioneine or a salt thereof for preventing, alleviating, or ameliorating heatstroke.

16. Use of L-ergothioneine or a salt thereof for preventing, alleviating, or ameliorating dehydration.

17. Use of L-ergothioneine or a salt thereof for regulating intracellular and extracellular water.